United States Patent [19]

Lubec

[11] **Patent Number: 5,077,313**

[45] **Date of Patent: Dec. 31, 1991**

[54] **PROCESS FOR INHIBITING PATHOLOGICAL COLLAGEN CROSS-LINKING IN DIABETES PATIENTS**

[76] Inventor: **Gert Lubec**, Brodschekhof 14, A-1220 Wien, Austria

[21] Appl. No.: **367,474**

[22] Filed: **Jun. 16, 1989**

[30] **Foreign Application Priority Data**

Nov. 25, 1988	[AT]	Austria	A 2903/88
Mar. 6, 1989	[AT]	Austria	A 498/89
Apr. 20, 1989	[EP]	European Pat. Off.	89890116.0

[51] **Int. Cl.**[5] **A61K 31/195**; A61K 31/155

[52] **U.S. Cl.** **514/565**; 514/634; 514/866

[58] **Field of Search** 514/561, 866, 565, 634

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,308,257	12/1981	Caspe	424/180
4,758,583	7/1988	Cerami et al.	514/399

FOREIGN PATENT DOCUMENTS

0222313	5/1987	European Pat. Off. .
56-133213	10/1981	Japan .
2078516	6/1980	United Kingdom .

OTHER PUBLICATIONS

Extra Cellular Matrixes, p. 179, in Molecular Cell Biology Ed. by Darnell et al., 1986.

"Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking", *Science,* vol. 232, No. 4758, Jun. 27, 1986, by M. Brownlee et al., pp. 1629-1632.

"Insulin and Glucagon Secretion in the Elederly", *Chemical Abstracts,* vol. 100, Mar. 26-Apr. 9, 1984, Abstract No. 97106h, by A. Pezzarossa et al.

The Merck Index, Tenth Edition, p. 113 (Arginine), p. 114, (Arginine Glutamate), p. 240 (Canavanine), p. 28 (Agmatine).

"Metabolism of L-[guanidinooxy-14C]Canavanine in the Rat", *Chemical Abstracts,* vol. 108, Feb. 1-Feb. 15, 1988, Abstract No. 48892t, by D. Thomas et al.

Primary Examiner—Thurman K. Page
Assistant Examiner—G. S. Kishore
Attorney, Agent, or Firm—Young & Thompson

[57] **ABSTRACT**

Pathological collagen cross-linking, caused in diabetes patients on account of the higher glucose concentrations, may be inhibited by means of arginine, spermidine, creatine, or agmatine, or a pharmaceutically acceptable salt thereof, in the amount of 1 to 4 g/day.

3 Claims, 3 Drawing Sheets